波士顿1型与Aurolab人工角膜在角膜缘干细胞缺乏眼中的结局比较
单中心回顾性比较81眼严重双侧角膜盲继发角膜缘干细胞缺乏(LSCD)患者,分别植入波士顿1型人工角膜(44眼)或Aurolab人工角膜(37眼)。5年随访中两组的解剖保留率和功能恢复率差异均无统计学意义,总体最常见并发症为新发青光眼(59%)。
要点
- LSCD所致角膜盲中人工角膜是有效治疗选择。
- 波士顿Kpro与AuroKpro的5年解剖保留和功能恢复无显著差异。
- 总体新发青光眼发生率为59%,两组间无显著差异。
核心结论
- 人工角膜是LSCD继发角膜盲的有效治疗选择。
- 在LSCD常见地区,AuroKpro可作为波士顿Kpro的替代选择。
研究设计与样本
- 单中心回顾性比较病例系列,纳入81眼严重双侧角膜盲继发LSCD患者。
- 波士顿1型人工角膜组44眼,Aurolab人工角膜组37眼。
- 主要结局为每年至5年随访的解剖保留率和视力恢复至20/200或更好。
主要发现
- 总体最常见适应证为化学伤(64.2%)。
- 解剖保留率波士顿Kpro组为68.2%(30/44),AuroKpro组为62.2%(23/37),p=0.89。
- 5年Kaplan-Meier生存率:解剖保留波士顿Kpro组58.51%±9% vs AuroKpro组43.8%±12%,p=0.23;功能恢复42.61%±8% vs 35.03%±10%,p=0.9,均无统计学意义。
- 总体最常见并发症为新发青光眼(59%,48/81),两组间发生率差异无统计学意义(p=0.09)。
临床怎么用
- 对于LSCD所致角膜盲,人工角膜植入可考虑用于解剖和功能恢复。
- 在缺乏波士顿Kpro的情况下,AuroKpro可作为替代设备使用。
局限性
- 单中心回顾性设计可能引入选择偏倚。
- 样本量有限(81眼),可能影响统计效能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To analyse the outcomes of keratoprosthesis in eyes with limbal stem cell deficiency (LSCD) and to compare the outcomes in two different keratoprosthesis devices. METHODS: This was a single-centre retrospective comparative case series which included 81 eyes of patients with severe bilateral corneal blindness secondary to LSCD. The patients underwent either Boston type 1 keratoprosthesis (Boston Kpro, n=44) or Aurolab keratoprosthesis (AuroKpro, n=37) implantation. The primary outcome measures of anatomical retention and functional recovery of 20/200 or better visual acuity at yearly time points until 5 years of follow-up were compared between the two groups. RESULTS: The most common indication overall was chemical injury (64.2%). Anatomical retention rates were similar in the Boston Kpro (30/44, 68.2%) and AuroKpro (23/37, 62.2%) groups (p=0.89). Kaplan-Meier survival rates at 5 years of follow-up were greater for the Boston Kpro group with respect to both anatomical retention (58.51%±9% vs 43.8±12%; p=0.23) as well as functional recovery (42.61%±8% vs 35.03±10%; p=0.9); these differences were not statistically significant. Overall, the most common complication was new-onset glaucoma (59%; 48/81). The difference in incidence rate of this complication was not statistically significant among the two groups (p=0.09). CONCLUSION: Keratoprosthesis is an effective treatment option for patients with corneal blindness secondary to LSCD. In a setting where LSCD is a common cause of corneal blindness, the AuroKpro, when available can be considered an alternative to the Boston Kpro to achieve anatomical and functional success in patients who otherwise would not have access to this device.
引用
- Shanbhag SS, Senthil S, Mohamed A, et al. Outcomes of the Boston type 1 and the Aurolab keratoprosthesis in eyes with limbal stem cell deficiency. Br J Ophthalmol. 2020. PMID: 32554443. doi:10.1136/bjophthalmol-2020-316369
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。